Introduction

The artificial intelligence sector continues to generate excitement, yet not all AI‑related companies have kept pace with market enthusiasm. Two such companies, Recursion Pharmaceuticals (RXRX) and Fiverr (FVRR), have experienced notable price drops, prompting contrarian investors to reassess their potential. Understanding why these stocks are down and what could drive a rebound is essential for anyone looking to balance risk and reward in a tech‑focused portfolio.

Recursion Pharmaceuticals: AI‑Powered Drug Development

Recursion applies artificial intelligence to accelerate drug discovery by running virtual experiments that prioritize candidates for clinical trials. The company aims to improve the success rate of new compounds compared to industry averages, potentially delivering drugs faster and at lower cost. However, Recursion has yet to bring a product to market, with no approved therapies or late‑stage candidates currently in its pipeline. This lack of tangible results contributes to its depressed valuation.

Despite the current setbacks, Recursion’s most promising candidate, REC‑4881, targets familial adenomatous polyposis (FAP), a rare disease that can lead to colorectal cancer. Early trial data show a significant reduction in polyp burden, and approval of this therapy could validate the company’s AI approach, potentially boosting its stock price. Investors must weigh the upside of a breakthrough against the risk of clinical or regulatory hurdles that could further impact the share price.

Fiverr: Shifting Toward Higher‑Value Freelance Projects

Fiverr operates a marketplace that connects freelancers with businesses needing a wide range of services. Initially known for low‑cost gigs starting at $5, the platform has increasingly attracted larger projects worth $1,000 or more. This strategic shift aims to capture more complex work that AI cannot easily automate, thereby increasing spend per buyer and strengthening revenue prospects.

While Fiverr’s revenue has recently moved in the wrong direction and active buyers have declined, the company reported improved net income, indicating better cost management. The challenge remains whether the new focus on high‑value projects can reverse buyer decline and sustain long‑term growth. Contrarian investors may view the current discount as an opportunity if they believe the platform can successfully reposition itself.

Risks and Considerations

Both companies face substantial risks. Recursion’s reliance on unproven drug candidates means it could encounter clinical setbacks or fail to secure regulatory approval, which would likely depress its stock further. Fiverr must contend with competition from AI‑based tools that can automate some freelance tasks, potentially eroding its gig market.

Investors should also be aware of broader market dynamics. AI stocks have been volatile, and sentiment can shift quickly based on macroeconomic trends or sector‑wide news. A thorough assessment of each company’s financial health, pipeline progress, and strategic execution is required before committing capital.

Conclusion

Recursion Pharmaceuticals and Fiverr represent two distinct approaches to leveraging artificial intelligence—one in biotech drug discovery and the other in the freelance economy. While both are currently beaten‑down, they each possess catalysts that could trigger a price rebound if they navigate their respective hurdles successfully. Contrarian investors who conduct diligent research may find these AI stocks worth a measured position, balancing the potential for high reward against the inherent risks of emerging technologies.